Aurum Biosciences, a clinical stage biopharmaceutical company based in Scotland has been awarded an Innovation Passport for its breakthrough stroke technology A 2015 spinout company of InnoScot Health, NHS Greater Glasgow and Clyde, and the University of Glasgow, Aurum Biosciences develops therapeutics and diagnostics in areas of unmet clinical need. Aurum Biosciences’ lead product ABL-101 … Read more
Glasgow-based novel biopharmaceuticals company Aurum Biosciences has appointed a new CEO as it looks to further expand its global presence A 2015 clinical stage spinout company of InnoScot Health, NHS Greater Glasgow and Clyde, and the University of Glasgow, Aurum Biosciences develops breakthrough therapeutics and diagnostics in areas of unmet clinical need. Its patented ABL-101 … Read more
Aurum Biosciences Receives £670k in New Equity Funding Round Aurum Biosciences Ltd (Aurum) has raised approximately £670k as part of a new round of equity funding. This funding round was supported by Infinion Biopharma Limited (Infinion), the Scottish Investment Bank, Scottish Health Innovations Ltd (SHIL), TRICAPITAL business angel syndicate and individual investors. Aurum is a … Read more
ABL-101 Found to be a Promising Candidate for Use in Inflammation Imaging Aurum in collaboration with an MRI research group based in Lausanne, Switzerland, led by Dr Ruud van Heeswijk and Dr Emeline Darçot, have tested the potential of ABL-101 to be used as an MRI inflammation diagnostic. This pre-clinical work, which was conducted on … Read more
Aurum Biosciences Has Second Patent Granted in the EU Aurum Biosciences are pleased to announce that that they have been granted a second EU patent for their ABL-101 imaging technology. This patent will add to Aurum’s growing portfolio of intellectual property protection for the diagnostic technology, which Aurum are currently developing for use in acute … Read more
Aurum Attending 2018 Bio-Europe Partnering Conference Aurum Biosciences Ltd (www.aurumbiosciences.com), a clinical stage company which has developed an innovative technology that has the potential to save and improve the lives of thousands of people who’ve had a stroke, will be attending the 2018 Bio-Europe Partnership Conference in Copenhagen from the 5th- 7th of November 2018 … Read more
Aurum Publishes Paper on ABL-101 Technology Aurum Biosciences Ltd, in collaboration with colleagues at the University of Glasgow and NHS Greater Glasgow and Clyde, have had a paper published in the journal Theranostics* (Impact factor 8.766). The paper describes work conducted at the university’s GEMRIC pre-clinical 7T scanner which investigated the use of Aurum’s ABL-101 … Read more
Aurum Attending Bio International Convention Aurum Biosciences Ltd (www.aurumbiosciences.com), a clinical stage company which has developed an innovative technology that has the potential to save and improve the lives of thousands of people who’ve had a stroke, will be attending the 2018 BIO International Convention in Boston on the 4-7th June. CEO Jim McGuire … Read more
Aurum Biosciences Attending Biotech Showcase in San Francisco Aurum Biosciences Ltd (www.aurumbiosciences.com), a company which has developed an innovative technology with the potential to save and improve the lives of thousands of people who’ve had a stroke, will be attending the Biotech Showcase event in San Francisco between the 8th – 10th January, 2018. CEO … Read more
Aurum Biosciences receives UK regulatory approval for a Phase 2 trial of ABL-101 in stroke patients Aurum Biosciences Ltd (www.aurumbiosciences.com), a Glasgow-based biopharmaceutical company developing a novel, first-in-class stroke therapy and diagnostic, has received approval from the UK regulatory authority (MHRA) for a Phase 2 clinical trial due to start in Q1 2018. Aurum is developing … Read more